ERBB3 and cancer: A prior report demonstrated that neoadjuvant ADT induced prostate CAF secretion of the HER3 ligand, neuregulin 1β (NRG1β), in nearly a fifth of localized prostate cancers and increased resistance to antiandrogens through HER3 signaling in adjacent cancer cells (21).